Market Overview:
The global azilsartan medoxomil API market is expected to grow at a CAGR of 5.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of hypertension and rising demand for novel therapeutics for the treatment of hypertension. The market is segmented on the basis of type, application, and region. On the basis of type, it is divided into min purity less than 98%, min purity 98%-99%, and min purity more than 99%. By application, it is classified into research and pharmaceuticals. Geographically, it is analyzed across North America, Latin America, Europe, Asia Pacific (APAC), and Middle East & Africa (MEA). Some key players operating in this market are Novartis AG (Switzerland), Pfizer Inc.(U.S.), Sanofi SA(France), Merck & Co., Inc.(U.S.), AstraZeneca plc(U.K.), Bayer AG(Germany), Takeda Pharmaceutical Company Limited (Japan), Eli Lilly and Company (U.S.), GlaxoSmithKline plc.( U . K .
Product Definition:
Azilsartan Medoxomil API is a drug used to treat high blood pressure. It belongs to a class of drugs called angiotensin receptor blockers (ARBs). Azilsartan Medoxomil inhibits the action of angiotensin II, which causes the muscles around blood vessels to contract. This relaxation allows more blood to flow through the vessels and lowers blood pressure.
Min Purity Less Than 98%:
Min Purity Less Than 98% is the most preferred type of Azilsartan Medoxomil API. It has a purity level of 99.5%. This product is used in the preparation of various medicines for treatment against hypertension, angina pectoris and coronary heart diseases among others.
Min Purity 98%-99%:
Min Purity 98%-99% is a special type of purity grade prepared for pharmaceutical and biotechnology industries. It contains very low impurities (less than 0.5%) on a weight basis, as compared to the other standard commercial grades such as USP-NF and USP-NF3 which contain around 3%-8% impurities on a weight basis.
Application Insights:
The research application dominated the overall market in terms of revenue share in 2017. The pharmaceutical segment is expected to witness the fastest growth over the forecast period. Factors such as increasing healthcare spending, growing geriatric population, and rising number of cardiovascular diseases are anticipated to drive demand for azilsartan medoxomil APIs.
Pharmaceutical is one of the key applications driving this industry due to high prevalence of heart related disorders coupled with aging population across various regions including North America and Europe.
Regional Analysis:
North America dominated the global market in 2017. The presence of key players, favorable reimbursement policies, and high healthcare expenditure are some of the factors responsible for its dominance. In addition, increasing prevalence of diabetes is expected to drive demand for Azilsartan Medoxomil in this region. For instance, as per American Diabetes Association (ADA), Inc., around 29 million people were diagnosed with diabetes in U.S., and another 86 million were estimated to have prediabetes which eventually lead to type 2 diabetes if not treated properly.
Asia Pacific is anticipated to be the fastest-growing regional market during the forecast period owing to rising healthcare expenditure by governments.
Key Companies Present In The Market And Their Drug Profiles: Pfizer; Sanofi; Allergan; Actavis/Bayer AG; Novartis AG.
Growth Factors:
- Increasing prevalence of hypertension and other cardiovascular diseases: The global prevalence of hypertension is estimated to be around 1.13 billion in 2015 and is projected to reach 1.56 billion by 2025. This will create a large pool of patients who will require treatment, thereby driving the demand for azilsartan medoxomil API.
- Growing geriatric population: The global geriatric population is expected to grow at a CAGR of 6% from 2016 to 2020, creating a large pool of patients with age-related cardiovascular diseases that will need treatment with azilsartan medoxomil API drugs.
- Technological advancements in the field of drug discovery and development: Azilsartan medoxomil API has been developed using advanced technologies such as high-throughput screening (HTS) and molecular modeling which have helped reduce the time taken for drug development process considerably . This will help fuel the demand for azilsartan medoxomil API in the coming years .
Scope Of The Report
Report Attributes
Report Details
Report Title
Azilsartan Medoxomil API Market Research Report
By Type
Min Purity Less Than 98%, Min Purity 98%-99%, Min Purity More Than 99%
By Application
Research, Pharmaceutical
By Companies
Tecoland, FCDA, A ChemTek, Clearsynth, Ami Lifesciences, Metrochem API, SGMR Pharmaceuticals, Beijing Xinyitai, Hubei Lansun Biochemistry Pharmaceutical, Rundu Pharma, Tianyu Pharm, Jiangxi Synergy Pharmaceutical
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
160
Number of Tables & Figures
112
Customization Available
Yes, the report can be customized as per your need.
Global Azilsartan Medoxomil API Market Report Segments:
The global Azilsartan Medoxomil API market is segmented on the basis of:
Types
Min Purity Less Than 98%, Min Purity 98%-99%, Min Purity More Than 99%
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Research, Pharmaceutical
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Tecoland
- FCDA
- A ChemTek
- Clearsynth
- Ami Lifesciences
- Metrochem API
- SGMR Pharmaceuticals
- Beijing Xinyitai
- Hubei Lansun Biochemistry Pharmaceutical
- Rundu Pharma
- Tianyu Pharm
- Jiangxi Synergy Pharmaceutical
Highlights of The Azilsartan Medoxomil API Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Min Purity Less Than 98%
- Min Purity 98%-99%
- Min Purity More Than 99%
- By Application:
- Research
- Pharmaceutical
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Azilsartan Medoxomil API Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Azilsartan Medoxomil API is a prescription medication used to treat hypertension. It works by decreasing the amount of blood that flows through your veins.
Some of the major players in the azilsartan medoxomil api market are Tecoland, FCDA, A ChemTek, Clearsynth, Ami Lifesciences, Metrochem API, SGMR Pharmaceuticals, Beijing Xinyitai, Hubei Lansun Biochemistry Pharmaceutical, Rundu Pharma, Tianyu Pharm, Jiangxi Synergy Pharmaceutical.
The azilsartan medoxomil api market is expected to grow at a compound annual growth rate of 5.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Azilsartan Medoxomil API Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Azilsartan Medoxomil API Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Azilsartan Medoxomil API Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Azilsartan Medoxomil API Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Azilsartan Medoxomil API Market Size & Forecast, 2020-2028
4.5.1 Azilsartan Medoxomil API Market Size and Y-o-Y Growth
4.5.2 Azilsartan Medoxomil API Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Min Purity Less Than 98%
5.2.2 Min Purity 98%-99%
5.2.3 Min Purity More Than 99%
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Research
6.2.2 Pharmaceutical
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Azilsartan Medoxomil API Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Azilsartan Medoxomil API Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Min Purity Less Than 98%
9.6.2 Min Purity 98%-99%
9.6.3 Min Purity More Than 99%
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Research
9.10.2 Pharmaceutical
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Min Purity Less Than 98%
10.6.2 Min Purity 98%-99%
10.6.3 Min Purity More Than 99%
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Research
10.10.2 Pharmaceutical
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Min Purity Less Than 98%
11.6.2 Min Purity 98%-99%
11.6.3 Min Purity More Than 99%
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Research
11.10.2 Pharmaceutical
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Min Purity Less Than 98%
12.6.2 Min Purity 98%-99%
12.6.3 Min Purity More Than 99%
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Research
12.10.2 Pharmaceutical
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Min Purity Less Than 98%
13.6.2 Min Purity 98%-99%
13.6.3 Min Purity More Than 99%
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Research
13.10.2 Pharmaceutical
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Azilsartan Medoxomil API Market: Competitive Dashboard
14.2 Global Azilsartan Medoxomil API Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Tecoland
14.3.2 FCDA
14.3.3 A ChemTek
14.3.4 Clearsynth
14.3.5 Ami Lifesciences
14.3.6 Metrochem API
14.3.7 SGMR Pharmaceuticals
14.3.8 Beijing Xinyitai
14.3.9 Hubei Lansun Biochemistry Pharmaceutical
14.3.10 Rundu Pharma
14.3.11 Tianyu Pharm
14.3.12 Jiangxi Synergy Pharmaceutical
